Compare PGEN & BBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | BBCP |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 345.5M |
| IPO Year | 2013 | 2017 |
| Metric | PGEN | BBCP |
|---|---|---|
| Price | $4.12 | $7.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $8.33 | $8.25 |
| AVG Volume (30 Days) | ★ 5.1M | 151.4K |
| Earning Date | 05-13-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $230,981,000.00 | ★ $392,867,000.00 |
| Revenue This Year | $1,115.92 | $3.49 |
| Revenue Next Year | $81.04 | $0.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $5.22 |
| 52 Week High | $5.47 | $7.80 |
| Indicator | PGEN | BBCP |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 54.38 |
| Support Level | $4.02 | $6.65 |
| Resistance Level | $4.44 | $7.27 |
| Average True Range (ATR) | 0.31 | 0.27 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 87.04 | 67.74 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.